A Phase 4 interventional study of iTEAR100 treatment in Dry Eye, sponsored by Olympic Ophthalmics, Inc.. Status unknown at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.
Sponsored by Olympic Ophthalmics, Inc. · Phase 4, Interventional, and Treatment
iTEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed.
TEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed. At both exam days, a Schirmer test before and after will be performed as well as parameters which indicate immediate effect of treatment and treatment over the 30 days.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Olympic Ophthalmics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient receive iTEAR100 treatment
Device: iTEAR100 treatment
Vibratory energy to the external nasal nerve
Schirmer score
Difference between Schirmer score measured before stimulation and after stimulation at each visit
Time frame: within 5 minutes of stimulation
Symptom Scores
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Olympic Ophthalmics, Inc.